Pharmaceutical Research Grant

Pharmaceutical Research Grant

Industry Role
(Pharma / Equipment)		 Type of Research Proposal ISCCM Policy
Company proprietary item related (New drug / Device) Phase 0 / 1 / 2 / 3
  • ISCCM not to be involved And
  • No endorsement by ISCCM

(Note: Challenges of approvals, safety concerns, insurances etc.)
Company proprietary item related (New drug / Device) Post marketing surveillance (PMS)
  • ISCCM not to be involved And
  • No endorsement by ISCCM

(Note: A PMS might send the message that ISCCM is endorsing a new drug/product)
Company grants (restricted or unrestricted) to ISCCM for a particular study proposal Study proposal or idea, not related to propriety item, by the Company (e.g. existing drugs, new indications)
  • ISCCM should be allowed to modify proposal giving merit to scientific content.
  • Once approved, ISCCM through its Research Committee will create a Steering Committee for the particular study.
  • Steering committee will be responsible for all administrative approval (including ethical approval, CTRI registration, insurance cover, DCGI approval etc.). A Clinical Research Officer (CRO) may be appointed by ISCCM and supported by the company for this
  • Data ownership, analysis, manuscript writing, publication will be exclusively with the ISCCM. The company will play no role in analysis and write up.
  • Manuscript will be submitted first to IJCCM, by Steering committee, for possible publication.
  • ISCCM will provide study progress updates to Company / pharma industries on periodic basis.
  • The support of the company will be acknowledged in in the published work
Company grants (restricted or unrestricted) to ISCCM for a particular area of research through ISCCM ISCCM members (Principal Investigator) can apply for the study proposal in that particular area of research
  • ISCCM can suggest modifying study proposal giving merit to scientific content
  • There will be a MoU between the Principal Investigator and ISCCM.
  • Principal Investigator will be responsible for all administrative approval (including ethical approval, CTRI registration, insurance cover, DCGI approval etc.). A CRO may be supported by the company for this purpose.
  • Data ownership will be held jointly by Principal Investigator and the ISCCM.
  • Principal Investigator will submit study progress report periodically to Research Committee, ISCCM as per society current policy.
  • Principal Investigator will be responsible for data integrity, data analysis and manuscript writing.
  • Principal Investigator will submit manuscript first to IJCCM for possible publication. If rejected by IJCCM, then after informing ISCCM can submit to another journal.
  • In all manuscript, arise out of the study, Funding source and acknowledgement of ISCCM support to be mentioned.
  • Principal investigator will not oblige compulsory to include ISCCM office bearer as author of the manuscript.